azacitidine has been researched along with Adrenocortical Carcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Creemers, SG; de Herder, WW; Dogan, F; Eekhoff, EM; Feelders, RA; Franssen, GJ; Hofland, LJ; Janssen, JA; Papathomas, TG; van der Valk, P; van Kemenade, FJ; van Koetsveld, PM | 1 |
| Clark, OH; Duh, QY; Fernandez-Ranvier, G; Kebebew, E; Shen, WT; Suh, I; Weng, J | 1 |
| Åkerström, G; Björklund, P; Carling, T; Choi, M; Fonseca, AL; Hellman, P; Kugelberg, J; Lifton, RP; Scholl, U; Starker, LF; Westin, G | 1 |
3 other study(ies) available for azacitidine and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Adenoma; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Child; Decitabine; DNA Methylation; Female; Humans; Insulin-Like Growth Factor II; Male; Middle Aged; Regulatory Sequences, Nucleic Acid; RNA, Messenger; Young Adult | 2016 |
Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells.
Topics: Adrenocortical Carcinoma; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Drug Screening Assays, Antitumor; Humans; Tumor Cells, Cultured | 2010 |
Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
Topics: Adenoma; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Genome-Wide Association Study; Humans; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic | 2012 |